8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 27, 2026·SEC
Q32 Bio Inc.(QTTB)Earnings, Financials & Key Ratios
QTTB•NASDAQ
5.2× P/E·Price updated Jun 11, 2026
AboutQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Show more
- Revenue$54M
- EBITDA$17M+126.4%
- Net Income$30M+162.5%
- EPS (Diluted)2.42+136.8%
- Gross Margin99.27%
- EBITDA Margin32.18%
- Operating Margin31.45%
- Net Margin55.49%
- ROE125.06%+114.9%
- Debt/Equity0.37-89.0%
- Interest Coverage15.37+110.1%
QTTB Key Insights
Q32 Bio Inc. (QTTB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Strong 5Y sales CAGR of 81.9%
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when QTTB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QTTB Price & Volume
Q32 Bio Inc. (QTTB) stock price & volume — 10-year historical chart
Loading chart...
QTTB Growth Metrics
Q32 Bio Inc. (QTTB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years81.85%
3 Years100.66%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM155.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM153.85%
Return on Capital
10 Years-73.34%
5 Years-88.04%
3 Years-118.86%
Last Year26.77%
QTTB Recent Earnings
Q32 Bio Inc. (QTTB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 1/12 qtrs (25%)
Q2 2026Latest
May 5, 2026EPS
$0.54
Est $0.52
-3.8%
Revenue
—
Q2 2026
Mar 10, 2026EPS
$3.65
Est $0.85
+529.4%
Revenue
$54M
Est $54M
+0.0%
Q4 2025
Nov 13, 2025EPS
$0.60
Est $1.39
+56.8%
Revenue
—
Q3 2025
Aug 6, 2025EPS
$0.78
Est $1.14
+31.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.54vs $0.52-3.8% | — |
| Q2 2026 | Mar 10, 2026 | $3.65vs $0.85+529.4% | $54Mvs $54M+0.0% |
| Q4 2025 | Nov 13, 2025 | $0.60vs $1.39+56.8% | — |
| Q3 2025 | Aug 6, 2025 | $0.78vs $1.14+31.6% | — |
Based on last 12 quarters of dataView full earnings history →
QTTB Peer Comparison
Q32 Bio Inc. (QTTB) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 CABA | 490.79M | 3.01 | -1.84 | -131.58% | 0.24 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 ALNY | 38.61B | 289.39 | 124.20 | 65.19% | 13.46% | 98.29% | 1.62 | |
 REGN | 63.53B | 611.48 | 14.74 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare QTTB vs Peers
Q32 Bio Inc. (QTTB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QTTB Income Statement
Q32 Bio Inc. (QTTB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 5.32M | 1.67M | 2.7M | 33.97M | 6.65M | -6.65M | 0 | 53.74M | 53.74M |
Revenue Growth % | - | - | -68.7% | 62.18% | 1157.25% | -80.42% | -200% | 100% | - | - |
Cost of Goods Sold | 684.21K | 0 | 0 | 0 | 9.54M | 0 | 0 | 487K | 391K | 271K |
COGS % of Revenue | - | - | - | - | 28.09% | - | - | - | 0.73% | - |
Gross Profit | -684.21K▲ 0% | 5.32M▲ 877.8% | 1.67M▼ 68.7% | 2.7M▲ 62.2% | 24.43M▲ 804.0% | 6.65M▼ 72.8% | -6.65M▼ 200.0% | -487K▲ 92.7% | 53.35M▲ 11054.0% | 53.47M▲ 0% |
Gross Margin % | - | 100% | 100% | 100% | 71.91% | 100% | 100% | - | 99.27% | 99.5% |
Gross Profit Growth % | -185.33% | 877.83% | -68.7% | 62.18% | 804.03% | -72.77% | -200% | 92.68% | 11054% | - |
Operating Expenses | 28.97M | 63.96M | 105.29M | 124.06M | 120.38M | 45.88M | 41.6M | 65.61M | 36.44M | 32.06M |
OpEx % of Revenue | - | 1201.78% | 6319.99% | 4591.45% | 354.35% | 689.76% | -625.53% | - | 67.82% | - |
Selling, General & Admin | 7.6M | 16.01M | 15.89M | 23.67M | 27.29M | 10.06M | 9.88M | 17.47M | 17.68M | 17.08M |
SG&A % of Revenue | - | 300.85% | 953.96% | 875.98% | 80.34% | 151.29% | -148.47% | - | 32.9% | - |
Research & Development | 21.38M | 47.95M | 89.4M | 100.39M | 93.08M | 35.81M | 31.73M | 48.14M | 19.16M | 15.25M |
R&D % of Revenue | - | 900.94% | 5366.03% | 3715.47% | 274.01% | 538.48% | -477.06% | - | 35.65% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -391K | -271K |
Operating Income | -29.66M▲ 0% | -59.93M▼ 102.1% | -109.94M▼ 83.5% | -130.26M▼ 18.5% | -95.95M▲ 26.3% | -39.23M▲ 59.1% | -48.26M▼ 23.0% | -66.1M▼ 37.0% | 16.9M▲ 125.6% | 21.41M▲ 0% |
Operating Margin % | - | -1126.01% | -6599.22% | -4820.98% | -282.44% | -589.76% | 725.53% | - | 31.45% | 39.84% |
Operating Income Growth % | -196.57% | -102.06% | -83.46% | -18.48% | 26.34% | 59.12% | -23.02% | -36.98% | 125.57% | - |
EBITDA | -28.97M | -58.64M | -103.63M | -121.36M | -86.41M | -38.85M | -47.76M | -65.61M | 17.29M | 21.77M |
EBITDA Margin % | - | -1101.78% | -6219.99% | -4491.45% | -254.35% | -584.2% | 718.03% | - | 32.18% | 40.51% |
EBITDA Growth % | -196.85% | -102.38% | -76.72% | -17.11% | 28.8% | 55.03% | -22.91% | -37.4% | 126.36% | 134.55% |
D&A (Non-Cash Add-back) | 684.21K | 1.29M | 6.32M | 8.9M | 9.54M | 370K | 499K | 487K | 391K | 362K |
EBIT | -29.99M | -55.58M | -103.92M | -128.69M | -95.76M | -39.23M | -48.26M | -45.79M | 16.9M | 21.88M |
Net Interest Income | 0 | 0 | 6.03M | 1.57M | 185K | 0 | 0 | 3.6M | 1.1M | -100K |
Interest Income | 542.63K | 4.35M | 6.03M | 1.57M | 185K | 0 | 0 | 3.9M | 2.2M | 900K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300K | 1.1M | 1M |
Other Income/Expense | -333.37K | 4.35M | 6.03M | 1.57M | 185K | -3.52M | -5.17M | 18.39M | 12.92M | 11.83M |
Pretax Income | -29.99M▲ 0% | -55.58M▼ 85.3% | -103.92M▼ 87.0% | -128.69M▼ 23.8% | -95.76M▲ 25.6% | -42.75M▲ 55.4% | -53.42M▼ 25.0% | -47.71M▲ 10.7% | 29.82M▲ 162.5% | 33.24M▲ 0% |
Pretax Margin % | - | -1044.29% | -6237.45% | -4762.92% | -281.9% | -642.72% | 803.26% | - | 55.49% | 61.86% |
Income Tax | -4 | 0 | 0 | 0 | 0 | 62K | 318K | 21K | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.15% | -0.6% | -0.04% | 0% | 0% |
Net Income | -29.99M▲ 0% | -55.58M▼ 85.3% | -103.92M▼ 87.0% | -128.69M▼ 23.8% | -95.76M▲ 25.6% | -42.81M▲ 55.3% | -53.74M▼ 25.5% | -47.73M▲ 11.2% | 29.82M▲ 162.5% | 33.24M▲ 0% |
Net Margin % | - | -1044.29% | -6237.45% | -4762.92% | -281.9% | -643.65% | 808.04% | - | 55.49% | 61.86% |
Net Income Growth % | -272.7% | -85.31% | -86.98% | -23.84% | 25.59% | 55.3% | -25.54% | 11.18% | 162.47% | 155.6% |
Net Income (Continuing) | -29.99M | -55.58M | -103.92M | -128.69M | -95.76M | -42.81M | -53.74M | -47.73M | 29.82M | 33.24M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -14.42▲ 0% | -35.04▼ 143.0% | -44.41▼ 26.7% | -50.46▼ 13.6% | -31.18▲ 38.2% | -13.42▲ 57.0% | -16.70▼ 24.4% | -6.58▲ 60.6% | 2.42▲ 136.8% | 2.36▲ 0% |
EPS Growth % | -272.61% | -143% | -26.74% | -13.62% | 38.21% | 56.96% | -24.44% | 60.6% | 136.78% | 153.85% |
EPS (Basic) | -14.42 | -35.04 | -44.41 | -50.46 | -31.18 | -13.42 | -16.70 | -5.12 | 2.42 | - |
Diluted Shares Outstanding | 2.08M | 1.59M | 2.34M | 2.55M | 3.07M | 3.19M | 3.22M | 12.2M | 12.31M | 14.1M |
Basic Shares Outstanding | 2.08M | 1.59M | 2.34M | 2.55M | 3.07M | 3.19M | 3.22M | 12.2M | 12.3M | 14.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
QTTB Balance Sheet
Q32 Bio Inc. (QTTB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 131.6M | 221.69M | 266.58M | 219.56M | 191.91M | 46.85M | 28.72M | 81.88M | 55.05M | 57.2M |
Cash & Short-Term Investments | 129.66M | 214.74M | 262.39M | 217.43M | 155.87M | 43.89M | 25.62M | 77.97M | 48.3M | 50.75M |
Cash Only | 51.57M | 38.22M | 53.77M | 217.43M | 108.38M | 43.89M | 25.62M | 77.97M | 48.3M | 50.75M |
Short-Term Investments | 78.08M | 176.52M | 208.61M | 0 | 47.49M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 800K | 400K | 400K | 0 | 1.06M | 755K | 555K | 0 | 0 |
Days Sales Outstanding | - | 54.87 | 87.64 | 54.03 | - | 58.39 | -41.43 | - | - | 0.94 |
Inventory | 0 | 0 | 0 | 0 | 0 | 1.75M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.94M | 6.15M | 3.79M | 1.73M | 36.04M | 146K | 83K | 396K | 6.75M | 6.45M |
Total Non-Current Assets | 5.93M | 37.41M | 43.99M | 44.17M | 19.81M | 14.92M | 18.34M | 10.46M | 6.73M | 6.47M |
Property, Plant & Equipment | 3.15M | 35.64M | 42.72M | 42.9M | 17.86M | 9.17M | 8.08M | 7.09M | 6.08M | 5.83M |
Fixed Asset Turnover | - | 0.15x | 0.04x | 0.06x | 1.90x | 0.73x | -0.82x | - | 8.84x | 8.66x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.77M | 1.77M | 1.27M | 1.27M | 1.95M | 25.81M | 0 | 2.6M | 647K | 1.29M |
Other Non-Current Assets | 1M | 0 | 0 | 0 | 0 | -20.06M | 10.26M | 763K | 0 | 647K |
Total Assets | 137.53M▲ 0% | 259.09M▲ 88.4% | 310.57M▲ 19.9% | 263.74M▼ 15.1% | 211.72M▼ 19.7% | 61.77M▼ 70.8% | 47.06M▼ 23.8% | 92.33M▲ 96.2% | 61.78M▼ 33.1% | 63.67M▲ 0% |
Asset Turnover | - | 0.02x | 0.01x | 0.01x | 0.16x | 0.11x | -0.14x | - | 0.87x | 0.86x |
Asset Growth % | 867.21% | 88.39% | 19.87% | -15.08% | -19.72% | -70.82% | -23.82% | 96.21% | -33.09% | -144.06% |
Total Current Liabilities | 8.86M | 22.52M | 12.37M | 22.66M | 17.23M | 57.87M | 14.11M | 16.46M | 11.35M | 10.67M |
Accounts Payable | 2.54M | 15.73M | 2.61M | 4.72M | 2.37M | 1.44M | 3.47M | 2.99M | 879K | 653K |
Days Payables Outstanding | 1.35K | - | - | - | 90.49 | - | - | 2.24K | 820.55 | 1.15K |
Short-Term Debt | 0 | 0 | 0 | 2.5M | 246K | 32.4M | 878K | 3.1M | 6.93M | 6.24M |
Deferred Revenue (Current) | 3.34M | 770K | 809K | 5.63M | 3.21M | 14.53M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.98M | 6.02M | 8.96M | 9.8M | 11.41M | 2.79M | 3M | 5.68M | 3.54M | 3.78M |
Current Ratio | 14.85x | 9.84x | 21.54x | 9.69x | 11.14x | 0.81x | 2.04x | 4.97x | 4.85x | 5.36x |
Quick Ratio | 14.85x | 9.84x | 21.54x | 9.69x | 11.14x | 0.78x | 2.04x | 4.97x | 4.85x | 5.36x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.15K |
Total Non-Current Liabilities | 30.36M | 40.22M | 39.69M | 45.08M | 24.84M | 134.62M | 215.87M | 70.19M | 8.42M | 6.69M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 5.07M | 43.18M | 9.56M | 3.47M | 4.75M |
Capital Lease Obligations | 0 | 0 | 0 | 12.94M | 23.69M | 6.79M | 6.25M | 5.64M | 4.94M | 5.3M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 290.92K | 9.47M | 9.54M | 0 | 0 | 111.44M | 166.44M | 55M | 0 | 1.94M |
Total Liabilities | 39.22M | 62.74M | 52.06M | 67.74M | 42.07M | 192.49M | 229.98M | 86.66M | 19.76M | 17.36M |
Total Debt | 0 | 0 | 0 | 15.44M | 23.93M | 44.73M | 50.84M | 18.9M | 15.34M | 10.99M |
Net Debt | -51.57M | -38.22M | -53.77M | -201.99M | -84.45M | 838K | 25.22M | -59.06M | -32.95M | -39.76M |
Debt / Equity | - | - | - | 0.08x | 0.14x | - | - | 3.33x | 0.37x | 0.24x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.89x | 0.50x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -1.91x | -1.83x |
Interest Coverage | - | - | - | - | - | - | - | -152.62x | 15.37x | 21.88x |
Total Equity | 98.31M▲ 0% | 196.35M▲ 99.7% | 258.51M▲ 31.7% | 196M▼ 24.2% | 169.65M▼ 13.4% | -130.71M▼ 177.0% | -182.92M▼ 39.9% | 5.67M▲ 103.1% | 42.01M▲ 640.3% | 46.31M▲ 0% |
Equity Growth % | 1210.72% | 99.73% | 31.65% | -24.18% | -13.44% | -177.05% | -39.94% | 103.1% | 640.33% | 1556.77% |
Book Value per Share | 47.28 | 123.79 | 110.48 | 76.84 | 55.24 | -40.99 | -56.83 | 0.47 | 3.41 | 3.29 |
Total Shareholders' Equity | 98.31M | 196.35M | 258.51M | 196M | 169.65M | 177.98M | -182.92M | 5.67M | 42.01M | 46.31M |
Common Stock | 1.39K | 3K | 4K | 5K | 6K | 6K | 1K | 2K | 2K | 2K |
Retained Earnings | -40.18M | -95.76M | -199.67M | -328.37M | -424.13M | -429.14M | -187.08M | -234.81M | -204.99M | -212.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 604.89M | 0 | 0 | 0 | 0 |
Accumulated OCI | -73.31K | -77K | 183K | 0 | -7K | -404K | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QTTB Cash Flow Statement
Q32 Bio Inc. (QTTB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 6.48M | -42.56M | -91.36M | -94.33M | -109.75M | -10.96M | -18.68M | -67.72M | -33.54M | -27.4M |
Operating CF Margin % | - | -799.74% | -5483.67% | -3491.19% | -323.07% | -164.74% | 280.81% | - | -62.42% | - |
Operating CF Growth % | 176.36% | -756.95% | -114.65% | -3.26% | -16.35% | 90.02% | -70.46% | -262.56% | 50.46% | 225.49% |
Net Income | -29.99M | -55.58M | -103.92M | -128.69M | -95.76M | -42.81M | -53.74M | -47.73M | 29.82M | 33.24M |
Depreciation & Amortization | 684.21K | 1.29M | 6.32M | 8.9M | 9.54M | 370K | 499K | 487K | 391K | 215K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 1.24M | 1.43M | 4.39M | 5.25M | 3.99M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 2.42M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 715.96K | -644K | 5.78M | 13.94M | 18.27M | 876K | 6.82M | -15.22M | -64.97M | -4.74M |
Working Capital Changes | 34.72M | 10.56M | 463K | 11.52M | -41.8M | 26.94M | 26.32M | -9.64M | -4.04M | -2.38M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.72M | 4.38M | -4.45M | 2.46M | -2.49M | -1.24M | 2.03M | -1.04M | -2.11M | -2.06M |
Cash from Investing | -81.53M | -121.79M | -51.8M | 204.9M | -50.79M | -2.47M | -5K | 19.93M | 7M | 7M |
Capital Expenditures | -1.96M | -24.94M | -21.83M | -3.73M | -2.4M | -2.48M | -5K | -75K | 0 | 0 |
CapEx % of Revenue | - | 468.6% | 1310.5% | 138.16% | 7.05% | 37.36% | -0.08% | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 130M | 0 | 0 | 0 | 7M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -37.98M | 0 | 0 | 7M | 0 |
Cash from Financing | 115.23M | 150.99M | 158.21M | 53.09M | 52.17M | 30.07M | 406K | 95.14M | -3.13M | 5.67M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 30M | 300K | 7M | -3.13M | -4.69M |
Equity Issued (Net) | 115.23M | 150.99M | 158.21M | 53.09M | 52.17M | 69K | 106K | 42M | 0 | 10.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -17.47K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.14M | 0 | 0 |
Net Change in Cash | 40.18M▲ 0% | -13.35M▼ 133.2% | 15.55M▲ 216.5% | 163.66M▲ 952.2% | -109.05M▼ 166.6% | 16.65M▲ 115.3% | -8.37M▼ 150.3% | 47.35M▲ 665.8% | -29.67M▼ 162.7% | -14.73M▲ 0% |
Free Cash Flow | 4.52M▲ 0% | -67.5M▼ 1593.1% | -113.19M▼ 67.7% | -98.06M▲ 13.4% | -112.15M▼ 14.4% | -13.44M▲ 88.0% | -18.68M▼ 39.0% | -67.79M▼ 262.9% | -33.54M▲ 50.5% | -27.4M▲ 0% |
FCF Margin % | - | -1268.34% | -6794.18% | -3629.35% | -330.13% | -202.1% | 280.89% | - | -62.42% | -51% |
FCF Growth % | 143.17% | -1593.1% | -67.69% | 13.36% | -14.36% | 88.01% | -38.98% | -262.86% | 50.52% | 58.3% |
FCF per Share | 2.17 | -42.55 | -48.37 | -38.45 | -36.51 | -4.22 | -5.80 | -5.56 | -2.72 | -1.94 |
FCF Conversion (FCF/Net Income) | -0.22x | 0.77x | 0.88x | 0.73x | 1.15x | 0.26x | 0.35x | 1.42x | -1.12x | -0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 856K | 0 | 259K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QTTB Key Ratios
Q32 Bio Inc. (QTTB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -56.69% | -37.72% | -45.69% | -56.63% | -52.38% | -219.88% | - | -841.11% | 125.06% | 230.68% |
| Return on Invested Capital (ROIC) | -103.84% | -43.88% | -45.45% | -98.32% | -181.7% | - | - | - | - | -69.02% |
| Gross Margin | - | 100% | 100% | 100% | 71.91% | 100% | 100% | - | 99.27% | 99.5% |
| Net Margin | - | -1044.29% | -6237.45% | -4762.92% | -281.9% | -643.65% | 808.04% | - | 55.49% | 61.86% |
| Debt / Equity | - | - | - | 0.08x | 0.14x | - | - | 3.33x | 0.37x | 0.24x |
| Interest Coverage | - | - | - | - | - | - | - | -152.62x | 15.37x | 21.88x |
| FCF Conversion | -0.22x | 0.77x | 0.88x | 0.73x | 1.15x | 0.26x | 0.35x | 1.42x | -1.12x | -0.82x |
| Revenue Growth | - | - | -68.7% | 62.18% | 1157.25% | -80.42% | -200% | 100% | - | - |
Related:QTTB Dividend History·QTTB Revenue History·QTTB Price History·QTTB P/E History·QTTB Financial Ratios·QTTB Institutional Holders
QTTB SEC Filings & Documents
Q32 Bio Inc. (QTTB) SEC filings — annual & quarterly reports (10-K, 10-Q)
QTTB Frequently Asked Questions
Q32 Bio Inc. (QTTB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Q32 Bio Inc. (QTTB) reported $53.7M in revenue for fiscal year 2025.
Q32 Bio Inc. (QTTB) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Q32 Bio Inc. (QTTB) is profitable, generating $33.2M in net income for fiscal year 2025 (55.5% net margin).
Dividend & Returns
Q32 Bio Inc. (QTTB) has a return on equity (ROE) of 125.1%. This is excellent, indicating efficient use of shareholder capital.
Q32 Bio Inc. (QTTB) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.